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Effects of initiation and titration of a single pre-prandial dose
of insulin glulisine while continuing titrated insulin glargine
in type 2 diabetes: a 6-month ‘proof-of-concept’ study
D. R. Owens1,S .D .L u z i o 1, C. Sert-Langeron2 & M. C. Riddle3
1Diabetes Research Unit, Cardiff University, University Hospital Llandough, Penarth, UK
2sanoﬁ-aventis, Paris, France
3Oregon Health and Science University, Portland, OR, USA
Aim: Stepwise intensiﬁcation of insulin treatment to match the progressive decline of endogenous insulin secretion has been shown to be an
effective management strategy in type 2 diabetes mellitus (T2DM). The efﬁcacy of initiating and titrating a single bolus dose of insulin glulisine
to baseline insulin glargine plus oral hypoglycaemic agents (OHAs) was investigated.
Methods: This was a 6-month, parallel-group, randomized, open-label, Phase IV study conducted in the US, UK and Russia. People with
T2DM (HbA1c 7.5–9.5%) using any basal insulin underwent a 3-month run-in period on insulin glargine titrated to optimize fasting blood
glucose (BG) control. Those with HbA1c >7.0% were randomized to either continue prior therapy (n = 57) or to add a single dose of
insulin glulisine (n = 49) immediately prior to the main meal for a further 3 months. Two different titration algorithms were employed
for the bolus dose, targeting 2-h postprandial BG ≤135 mg/dL (≤7.5 mmol/l; Russia and UK) or pre-meal/bedtime BG 100–120 mg/dl
(5.5–6.7 mmol/l; US).
Results: HbA1c and fasting plasma glucose levels decreased during the run-in period. In the 3 months after randomization, more participants
in the basal-plus-bolus group reached HbA1c <7.0% than the basal-only control group (22.4 vs. 8.8%; p < 0.05), with signiﬁcantly greater
reduction of HbA1c (−0.37 vs. −0.11%; p = 0.0290). Rates of hypoglycaemia and mean weight change were comparable between the
treatment groups.
Conclusions: In people with T2DM inadequately controlled on basal insulin plus OHAs, adding a single injection of insulin glulisine prior to the
main meal signiﬁcantly improves glucose control without undesired side effects.
Keywords: basal insulin, basal-plus, rapid-acting insulin, type 2 diabetes mellitus
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Introduction
Overtime,themanagementoftype2diabetesmellitus(T2DM)
requiresprogressiveadjustmentoftherapytoachieveandmain-
tainadequateglycaemiccontrolinanattempttoreducetherisk
of vascular complications. The American Diabetes Association
(ADA)/EuropeanAssociationfortheStudyofDiabetes(EASD)
consensusstatementsuggestsbeginningpharmacotherapywith
metformin or, in cases of metformin intolerance, with either
a sulphonylurea or a thiazolidinedione, as needed [1]. If, sub-
sequently, individual or combinations of oral hypoglycaemic
agents (OHAs) are no longer adequate, introducing insulin
therapy in the formof an ‘intermediate-acting’or ‘long-acting’
(basal) insulin is amongst the next options. The Treat-to-
Target Trial showed that initiation and systematic titration of
insulin glargine using a simple algorithm enables a majority of
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individuals to achieve an HbA1c level <7% with low rates of
hypoglycaemia [2].
Thenexttherapeuticstephasbeenmuchdebated,theleading
options being (i) cessation of basal insulin and substitution
with twice-daily injections of premixed (rapid-acting plus
longer-acting) insulin preparations, or (ii) progression to a
basal–bolus insulin regimen by continuing basal insulin and
adding injections of rapid-acting insulin prior to each meal
as required [1]. Recognized limitations of the ﬁrst option
include limited ﬂexibility in insulin dose adjustment resulting
in the need for relatively strict lifestyle changes, more frequent
hypoglycaemia, and greater weight gain [3,4]. The second
option is limited by the inconvenience of more frequent self-
monitoring of blood glucose (BG) to guide dose titration and
thepotentialneedformultiplepreprandial(threetofour)daily
injections. A third alternative is to continue basal insulin and
prior OHA therapy and add a single prandial insulin injection
priortoanindividual’smainmeal [5].Evidencefortheefﬁcacy
andsafetyofthislatterstrategyremainsrelativelylimited.Here,
we report a multicentre, multinational, ‘proof-of-concept’
studyofthissequentialapproachusingtwodifferentalgorithms
for introducing and titrating the prandial insulin dose.DIABETES, OBESITY AND METABOLISM original article
Materials and Methods
Subjects
Eligible individuals for this study were men or women
with T2DM, aged 18–75 years, with a body mass index
of 25–45 kg/m2,a nH b A 1c level of 7.5–9.5% and treated
with a basal insulin (neutral protamine Hagedorn [NPH]
insulin, lente insulin, insulin glargine or insulin detemir)
in combination with metformin (≥1 g/day) for more than
3 months.Exclusioncriteriaincludedtype1diabetes,currentor
anticipated pregnancy; treatment with OHAs alone (including
thiazolidinediones) or exenatide, pramlintide or any other
insulin preparation (i.e. premixed or short-acting insulins).
Individuals with proliferative retinopathy or clinically relevant
cardiovascular,hepatic,renal,neurological,otherendocrineor
major disease were also excluded. Written informed consent
was obtained from all participants, and institutional review
board/independent ethics committee approval was obtained
for each participating study centre.
Study Design
This 6-month, parallel-group, randomized, open-label, Phase
IV study was conducted at 12 sites in the UK, 17 in the US
and four in Russia. It included an initial 1- to2-week screening
phase followed by a 3-month run-in period and a 3-month
randomized treatment period (ﬁgure 1A). There were 11 face-
to-face visits at weeks −2 (selection), 0 (study entry), 2, 4, 8,
10 (randomization), 12, 14, 16, 20 and 24 (ﬁnal visit), plus
telephone contact at weeks 1, 3, 6, 13, 15, 18 and 22.
During the run-in period, patients were transferred from
their prior basal insulin (if other than insulin glargine) to
insulin glargine, which was titrated seeking to achieve a fasting
BG target of ≤100 mg/dl (≤5.5 mmol/l) using the Treat-to-
Target Trial algorithm [2]. At the end of the run-in period,
individuals whose HbA1c remained ≥7.0% were randomized
(1 : 1), using an interactive voice response telephone system,
either to continue their current therapy (basal-only group)
or to add one dose of insulin glulisine prior to their main
meal (basal-plus-bolus group). Both treatment strategies were
continuedforaperiodofthreeadditionalmonths(randomized
treatment period).
Titration of the prandial dose of insulin glulisine was
performed once a week using one of two different algorithms
(Table 1). In the UK and Russia, insulin glulisine dose
adjustmentwasbasedonthe2-h,postprandialBGwithatarget
of ≤135 mg/dl (≤7.5 mmol/l), whereas in the US the target
was a pre-meal BG level of 100–120 mg/dl (5.5–6.7 mmol/l)
following the main meal, or at bedtime if the main meal was
dinner. The main meal was deﬁned as the meal resulting in the
highest postprandial BG value determined from a seven-point
daytime BG proﬁle (before and 2 h after each meal, and at
bedtime) conducted on three separate days in the week prior
to the randomization visit. The timing of insulin glulisine
administration was kept constant throughout the 3-month
randomized treatment period. Mean daily BG was calculated
as the mean of the seven-point BG proﬁles performed before
each visit and variability was characterized by the standard
deviations for the mean BG values.
Theprimaryoutcomewastheproportionofpatientsachiev-
ing HbA1c< 7.0% at endpoint (with last observation carried
forward).Secondaryoutcomesincluded changes in HbA1c,B G
proﬁles, weight, insulin dose and rates of hypoglycaemia.
Hypoglycaemic episodes were assessed and categorized as
asymptomatic, symptomatic, nocturnal symptomatic, severe
and severe nocturnal. Asymptomatic hypoglycaemia was
an event without clinical symptoms and conﬁrmed by a
documented BG level <60 mg/dl (3.3 mmol/l). Symptomatic
hypoglycaemia was deﬁned as an event with clinical symptoms
consistentwithhypoglycaemia,withorwithoutaconﬁrmatory
BG measurement, and associated with prompt recovery
after oral carbohydrate administration. Severe hypoglycaemia
was deﬁned as an event with symptoms consistent with
hypoglycaemia in which the patient required assistance from
another person, and the event was either conﬁrmed by a BG
<36 mg/dl (2.0 mmol/l) or recovery after oral carbohydrate,
intravenous glucose or glucagon administration.
Statistical Analysis
All primary and secondary outcomes, with the exception of
hypoglycaemia and adverse events, were assessed in a modiﬁed
intent-to-treat (mITT) population, deﬁned as all randomized
subjects who received study medication and who had an
HbA1c valuerecordedatenrolmentandduringtherandomized
treatmentperiod.Additionalanalysesfortheprimaryoutcome
and change in HbA1c were also performed for the per-
protocol population (PPP), a subset of the mITT population
that excluded patients with a major protocol violation. The
incidenceandratesofhypoglycaemiaandoccurrenceofadverse
events were analysed in the safety population, comprising all
treatedpatients.Achisquare(χ2)testwasusedtocomparethe
percentage of patients with HbA1c < 7% at endpoint. Analysis
ofcovariancewasusedforcontinuousvariables,withtreatment
usedastheﬁxedeffectandbaselinevalueasacovariate.Missing
data were imputed by carrying the last observation forward.
Atleast98patientswereneededtoberandomized(49ineach
arm)inordertodemonstratewith80%powerthattheaddition
of a single injection of insulin glulisine prior to the main meal
would bring over 40% of patients inadequately controlled
with insulin glargine alone plus OHAs to an HbA1c < 7%
compared with 15% of patients continuing insulin glargine
only plus OHAs (5% alpha risk, two-sided test). A ﬁnal sample
size of 196 patients was calculated by estimating that ∼50%
of patients would probably not be eligible for randomization
having achieved an HbA1c level <7.0% during the 3-month
run-in period or due to exclusion for other reasons.
Results
Participant Disposition
Patient enrolment commenced on 9 July 2006 and follow-up
of the last patient was completed on 20 August 2008. Of 249
candidates screened, 135 were deemed eligible and willing to
enter the run-in period (ﬁgure 1B). Of the 29 participants
withdrawn from the study during the run-in period, 19
were because of achievement of an HbA1c level <7% on
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Figure 1. (A) Study design and (B) patient disposition. OHA, oral hypoglycaemic agent; V, visit.
insulin glargine alone. Thus, 106 patients were randomized,
57 to the basal-only group and 49 to the basal-plus-bolus
group (PPP: n = 51 and 45). Characteristics of the total study
population at selection and the mITT population at selection
and at randomization are included in Table 2. Characteristics
of the randomized participants were comparable with the total
population and were balanced between the two treatment
groups. One participant from each of the treatment groups
withdrewduringtherandomizedtreatmentperiod;thereasons
forwithdrawalrecorded were ‘non-compliancewith treatment
procedures’ and ‘site error’.
Glycaemic Responses to Therapy
Transfer to insulin glargine and subsequent titration of dosage
duringtherun-inperiodimprovedthemeanHbA1cfrom8.5 ±
0.6% at selection to 7.9 ± 0.6% at randomization and fasting
plasmaglucose(FPG)from144.3 ± 39.0to111.4 ± 22.5m g / d l
(8.0 ± 2.2t o6 .2 ± 1.2 mmol/l), respectively (Table 2). After
3 months of randomized treatment, the reduction in HbA1c
fromthe time of randomizationwas signiﬁcantly greater in the
basal-plus-bolusgroupthaninthebasal-onlygroup(−0.37 vs.
−0.11%; p = 0.0290; Table 3). This ﬁnding was conﬁrmed in
the PPP (−0.40 vs. −0.13%; p = 0.0242). Reductions in mean
daily plasma glucose (PG) were also signiﬁcantly greater in
the basal-plus-bolus group (−15.0 vs. −2.1 mg/dl [−0.8 vs.
0.1 mmol/l]; p = 0.011; Table 3). The variability in mean daily
PG improved in the basal-plus-bolus group over the course of
the randomized treatment period, whilst remaining essentially
unchanged in the basal-only group (Table 3).
The primary endpoint, that is, achievement of an HbA1c
level <7% at the end of the randomized treatment period, was
reachedmorefrequentlybyparticipantsinthebasal-plus-bolus
groupthanthoseinthebasal-onlygroup(mITT:22.4 vs.8.8%;
p < 0.05;PPP:24.4 vs.7.8%,p = 0.0254)(Table 3).Withinthe
basal-plus-bolus group, 10, 14 and 25 patients injected insulin
glulisine either before breakfast, lunch or dinner, respectively.
Of these, two (20.0%), three (21.4%) and six (24.0%) reached
HbA1c < 7% at endpoint, respectively. The mean HbA1c at
endpoint in these three subgroups of the basal-plus-bolus arm
was 7.6 ± 0.7, 7.6 ± 0.8a n d7 .4 ± 0.5%, respectively, with no
differencebetweenthegroups.FewpatientsachievedanHbA1c
level<6.5%attheendofrandomizedtreatmentineithergroup
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Table 1. Insulin glulisine dose titration.
RussiaandUnitedKingdom
Calculation of the initial dose of insulin glulisine for the ﬁrst injection:
Dose of insulin glulisine prior to the main meal = PPBG of the main meal in mmol/l divided by 2
Treat to target: PPBG ≤135 mg/dl (7.5 mmol/l)
PPBG ≤135 mg/dL (7.5 mmol/l) No change
135 mg/dl (7.5 mmol/l) <PPBG ≤153 mg/dl (8.5 mmol/l) +1U
153 mg/dl (8.5 mmol/l) <PPBG ≤80 mg/dl (10 mmol/l) +2U
PPBG >180 mg/dl (10 mmol/l) +3U
At the discretion of the investigator, small decreases of 1 U of the dose of insulin glulisine are permitted in case of hypoglycaemia
UnitedStates
Calculation of the initial dose of insulin glulisine for the ﬁrst injection:
6 U prior to the main meal. At the same time, the insulin glargine dose was reduced by 6 U and then titrated again the next week
Treat to target: 100 mg/dl (5.6 mmol/l) <BG* ≤120 mg/dl (6.7 mmol/l)
120 mg/dl (6.7 mmol/l) <BG* ≤140 mg/ dl (7.8 mmol/l) +1U
140 mg/dl (7.8 mmol/l) <BG* ≤180 mg/ dl (10 mmol/l) +2U
BG* >180 mg/dl (10 mmol/l) +2U
At the discretion of the investigator, small decreases of 1 U of the dose of insulin glulisine are permitted in case of hypoglycaemia
∗Pre-meal or bedtime BG value. FPG, fasting plasma glucose; PPBG, postprandial blood glucose; BG, blood glucose.
(mITT:basal-plus-bolusgroupn = 2[4.1%];basal-onlygroup
n = 1 [1.8%].)
The reduction in HbA1c from randomization was greater
with the US titration algorithm compared with the version
used in the UK and Russia without reaching statistical
signiﬁcance (adjusted mean change from randomization to
study end: −0.44 vs. −0.18%; p = 0.0603). In addition, a
greater proportion of patients in the mITT achieved target
HbA1c < 7.0% with the US titration algorithm versus the
algorithm used in the UK and Russian centres, but this
difference was also not statistically signiﬁcant (34.8 vs. 11.5%;
p = 0.0516).
Insulin Doses and Distribution
The mean daily doses of NPH, insulin glargine and insulin
detemir used by participants in the mITT population prior
to study entry were 36.6, 37.6 and 43.7 units, respectively
(Table 2). In both treatment groups, the daily dose of basal
insulin glargine increased between the time of inclusion and
randomization by 16.3 ± 14.7a n d1 8 .5 ± 14.5 units in the
basal-plus-bolus and basal-only groups, respectively. At the
endoftherun-inperiod,participantsusedameandailydoseof
54.1unitsofinsulinglargine,withacomparabledosagebetween
the basal-plus-bolus and basal-only groups (Table 3). Between
randomization and endpoint, basal insulin doses increased by
2.0 ± 10.2 units in the basal-plus-bolus group and 6.8 ± 11.3
units in the basal-only group (Table 3). Within the basal-
plus-bolus group, mean doses of insulin glulisine initially
recommended at randomization were 5.3 ± 0.8, 5.6 ± 0.9
and 5.4 ± 1.0 units for participants taking insulin glulisine
at breakfast, lunch or dinner, respectively. These increased to
10.9 ± 7.2, 12.2 ± 6.8a n d1 4 .2 ± 6.3 units, respectively, at the
last visit.
Meaninsulinglargineandinsulinglulisinedosesatendpoint
were numerically higher for patients treated with the US
versus the UK/Russia titration algorithm. At study end, insulin
glargine doses were 0.64 ± 0.45 U/kg and 0.54 ± 0.22 U/kg
with the US and UK/Russia algorithms, respectively. Similarly,
insulin glulisine doses at study end were 0.17 ± 0.08 U/kg and
0.11 ± 0.05 U/kg, respectively.
Seven-Point Glucose Proﬁles
Figure 2 shows the PG proﬁles obtained at randomization
and endpoint for the two treatment groups. In the basal-
plus-bolus treatment group, most of the reduction in PG
levels over the randomized treatment period occurred after
lunch (p = 0.0046), before dinner (p = 0.0021), after dinner
(p = 0.0008) and before bedtime (p = 0.0279) (ﬁgure 2A).
There were no signiﬁcant differences in the proﬁles PG
at randomization and endpoint in the basal-only group
(ﬁgure 2B). In the three subgroups of participants taking a
bolus injection either atbreakfast,lunch or dinner, a reduction
in the measurement following the post-injection meal was
apparent (ﬁgure 3A–C), although these differences were not
tested for statistical signiﬁcance because of the small number
of subjects in each subgroup.
Hypoglycaemia
During the run-in period, a total of 57 patients reported
hypoglycaemia,including50withsymptomatic,26withasymp-
tomatic and 29 with nocturnal symptomatic hypoglycaemia.
Rates of all, symptomatic, asymptomatic and nocturnal hypo-
glycaemia were 10.5 ± 21.6, 8.5 ± 18.9, 2.0 ± 5.6 and 2.3 ±
5.9 episodes/patient–year, respectively. No episodes of severe
hypoglycaemia were reported during the run-in period. The
frequency of hypoglycaemia during the 3-month random-
ized treatment period continued to be low and rates did
not differ between the treatment groups (all reported hypo-
glycaemia [mean ± standard deviation] for control vs. basal
plus bolus groups, respectively: 11.1 ± 15.5v s .1 3 .4 ± 21.7
events/patient–year, p = 0.960; symptomatic hypoglycaemia:
8.9 ± 15.2v s .1 0 .9 ± 18.2, p = 0.544; asymptomatic hypogly-
caemia: 2.3 ± 5.2 vs. 2.5 ± 7.7, p = 0.936; nocturnal symp-
tomatic hypoglycaemia: 4.4 ± 10.2 vs. 2.0 ± 4.5, p = 0.307);
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Table 3. Clinical outcomes at study end.
Parameter Control Basal plus bolus p value
n 57 49
HbA1c
<7%, n (%) 5 (8.8) 11 (22.4) 0.0499∗
Total (%) 7.8 ± 0.9 7.5 ± 0.6 —
Adjusted change (%) (Endpoint–randomization) −0.11 ± 0.08 −0.37 ± 0.09 0.0290†
Daily meanPG, mg/dl (mmol/l)
Randomization 167.4 ± 39.4
(9.3 ± 2.2)
170.2 ± 27.9
(9.5 ± 1.6)
—
Endpoint 165.8 ± 37.5
(9.2 ± 2.1)
154.7 ± 28.6
(8.6 ± 1.6)
—
Adjusted change (Endpoint–randomization) −2.1 ± 3.4
(−0.1 ± 0.2)
−15.0 ± 3.7
(−0.8 ± 0.2)
0.0109†
Daily variability inPG, mg/dl (mmol/l)
Randomization 50.6 ± 26.9
(2.8 ± 1.5)
49.1 ± 18.4
(2.7 ± 1.0)
—
Endpoint 50.0 ± 21.7
(2.8 ± 1.2)
44.7 ± 21.0
(2.5 ± 1.2)
0.043‡
Daily insulindose,U(U/kg)
Insulin glargine
Randomization 55.2 ± 28.3
(0.59 ± 0.26)
52.8 ± 31.3
(0.57 ± 0.31)
—
Endpoint 62.2 ± 34.9
(0.65 ± 0.32)
54.7 ± 34.8
(0.59 ± 0.35)
—
Insulin glulisine
Randomization
—
5.4 ± 1.0
(0.06 ± 0.01)
—
Endpoint
—
12.8 ± 6.6
(0.14 ± 0.07)
—
Data are n (%), means ± standard deviation, or adjusted means ± standard error for change.
∗Chi square test.
†Analysis of covariance (ANCOVA) analysis on change adjusted on randomization value.
‡ANCOVA analysis on the rank variability at endpoint adjusted on the rank randomization variability. PG, plasma glucose.
severe symptomatic hypoglycaemia: 0.2 ± 1.1 vs. 0.0 ± 0.0,
p = 0.192; nocturnal severe symptomatic hypoglycaemia:
0.1 ± 1.0 vs. 0.0 ± 0.0; p = 0.364; p values calculated using
the Wilcoxon rank sum test).
Weight Change
Weight change during both the run-in period and the
randomized treatment period was small and not statistically
signiﬁcant.Meanbodyweightwas92.1and91.5 kgatselection,
92.9 and 91.5 kg at randomization and 92.5 and 92.2 kg at
last observation in the control and bolus groups, respectively.
There were no statistically signiﬁcant differences in weight
change between the treatment groups.
Safety and Tolerability
Threesubjectsexperiencedaseriousadverseeventintherun-in
period prior to randomization that required hospitalization;
theyincludedanginapectoris,foodpoisoningandhypertensive
crisis (n = 1 each). During the randomized treatment period,
20 (40.8%) and 28 (49.1%) subjects in the basal-plus-bolus
and basal-only control groups reported an adverse event,
respectively. Four adverse events during the treatment period
were considered to be serious, of which two were in the
basal-plus-bolus group (angina pectoris and atrial ﬁbrillation)
and two in the basal-only group (scleroderma and tendon
disorders). There were no deaths reported during the study.
Discussion
These results show that the addition of a single dose of insulin
glulisinepriortothemealwiththegreatestpostprandialglucose
excursion to ongoing basal insulin glargine plus OHAs signif-
icantly improved glycaemic control in terms of mean HbA1c
levels. Mean daily PG levels, variability in mean daily PG and
the diurnal PG proﬁle were also improved with the basal-plus-
bolus strategy versus basal only. Improved glycaemic control
was achieved without signiﬁcant increases in the frequency of
hypoglycaemia or weight gain. The ﬁndings of this study are
consistent with those of the Orals Plus Apidra and LANTUS
(OPAL) study [5] in which one injection of insulin glulisine
added to insulin glargine plus OHAs signiﬁcantly improved
HbA1c levels in people with T2DM, irrespective of whether the
prandial insulin was administered at breakfast or at the main
meal. The important difference between this and the OPAL
study is that the present study had a run-in period to dose
titrate insulin glargine prior to the addition of a single dose
of insulin glulisine in individuals with inadequate glycaemic
control whilst on insulin glargine plus OHAs.
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A
B
Figure 2. Seven-point self-monitored blood glucose proﬁles in the bolus
(A) and control(B) groups. Blood glucose was monitored before breakfast
(fasting),lunchanddinner,2 haftereachmeal,andbeforebedtime.Results
are means ± standard deviation. LOCF, last observation carried forward.
Both fasting hyperglycaemia and increments of glucose
after meals contribute to overall glycaemic exposure.
After improvement of fasting hyperglycaemia with basal
insulin therapy, much of the remaining glycaemic exposure
is due to postprandial excursions [6,7]. Therefore, when
HbA1c remains higher than 7% after fasting glucose has
been normalized or nearly normalized with basal insulin,
further improvement requires attention to postprandial
hyperglycaemia. The potential beneﬁts of limiting glycaemic
excursions may extend to reducing cardiovascular risk from
reducedglycaemicvariability [8,9].TheADA/EASDconsensus
statement recommends that attempts to intensify insulin
therapy should be undertaken if HbA1c levels remain above
target on a basal insulin-only regimen [1]. However, methods
to achieve this treatment intensiﬁcation have not been fully
investigated. In clinical practice, the main approaches are to
either add short-acting insulin at each meal (basal–bolus)
or switch to twice- or three-times-daily premixed insulin
regimens. Both approaches are relatively complex. Individuals
and clinicians may experience difﬁculties in optimizing
multiple insulin doses while avoiding hypoglycaemia thereby
necessitating frequent self-monitoring of blood glucose. It is
likely that the well-documented delay in advancing therapies
(clinical inertia) results in part from these complexities [10].
A
B
C
Figure 3. Effect of time of insulin glulisine injection (breakfast, n = 10
[A];lunch,n = 14[B];dinner,n = 25[C])onseven-pointself-monitored
blood glucose proﬁles. Results are means ± standard deviation. Arrow
indicates time of injection. LOCF, last observation carried forward.
The ﬁndings in this proof-of-concept study suggest that
a strategy of adding a single prandial insulin injection to
basal insulin may offer a more logical initial step for the
intensiﬁcation of insulin therapy in T2DM. The overall
reductioninHbA1cwasrelativelysmall,butwasachievedinjust
3 months of treatment, and without accompanying difﬁculty
withhypoglycaemiaorweightgain.Thismethodmightbemost
effective for individuals whose HbA1c values are only modestly
above the 7.0% target, perhaps in the 7.0–7.5% range. In the
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present study population, participants had been on insulin
for at least 2 years, and their mean HbA1c level was 8.5% at
enrolment and 7.9% at randomization, so that relatively few
attainedthe<7.0%goal.However,thisﬁrststepinintroducing
prandial insulin therapy may provide a starting point for
advancing to full basal–bolus treatment for those needing
further intensiﬁcation given individual clinical requirement
based on diabetes duration, age and risk of macrovascular
disease [11,12].
As a proof-of-concept study, this study has several
limitations. The number of patients enrolled was relatively
small, and the relatively short period of use of basal plus
prandialtherapyprobablyunderestimatedthepotentialglucose
loweringthatmighthaveresultedhaddose-titrationandfollow
up continued beyond 3 months. The clinical results with the
two algorithms employed were not clinically or statistically
different. There was a trend in favour of the US algorithm,
but the numbers of participants studied were too small to
permit a conclusion on this point. In addition, assignment of
the algorithms depended on country of residence rather than
randomization and so any comparison may be open to bias
duetocountry-speciﬁcfactors.Furtherstudiesarenecessaryto
adequately compare these two algorithms.
In conclusion, this study clearly supports the rationale,
safety and efﬁcacy of adding a single dose of insulin glulisine
to ongoing insulin glargine plus OHAs to improve HbA1c and
mean daily plasma BG when HbA1c targets have not been met.
This approach may serve as the ﬁrst logical step from basal
insulin plus OHA therapy to a more intensive insulin regimen
in the quest to achieve glycaemic targets that are appropriate
forclinicalneedswithoutrequiringafullbasal–bolusregimen,
with its inherent demands on the individual and their carer.
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